Latest Breaking News On - Oncology contact - Page 5 : comparemela.com

Mural Oncology to Host Investor Webcast on October 17

/PRNewswire/ Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023.

Caroline loewKatie joyceDave borahSandy coombsExchange commissionMural oncologyChief executive officerPrivate securities litigation reform actAnnual reportOncology contact

Cardiff Oncology (CRDF) Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer

Cardiff Oncology (CRDF) Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKiki patelFairooz kabbinavarJames levineMark erlanderRicha kumariOregon health science universityCardiff oncology incUniversity of pittsburgh medical centerGilmartin groupKnight cancer instituteClinical development planExchange commissionTaft communicationsCardiff oncologyChief executive officer

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0.

United statesKiki patelMark erlanderJames levineRicha kumariFairooz kabbinavarSmall cell lung cancer programTaft communicationsClinical development planOregon health science universityCardiff oncology incPrnewswire cardiff oncology incExchange commissionGilmartin groupUniversity of pittsburghKnight cancer institute

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical.

United statesKiki patelJames levineFairooz kabbinavarMark erlanderRicha kumariGilmartin groupUniversity of pittsburghPancreatic cancer programOregon health science universityCardiff oncology incPrnewswire cardiff oncology incKnight cancer instituteClinical development planSmall cell lung cancer programExchange commission

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug.

Richa kumariJames levineMark erlanderKiki patelGilmartin groupExchange commissionPfizer global product developmentDana farber cancer institutePrnewswire cardiff oncology incCardiff oncology incMedicine team group lead for breast cancerTaft communicationsCardiff oncologyChief executive officerPfizer igniteVice president